289483-87-0

Usage

Uses

Used in Pharmaceutical Industry:
7-amino-4-methyl-1H-indole-3-carbonitrile is used as a precursor for the synthesis of various pharmaceutical compounds. Its versatile structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
7-amino-4-methyl-1H-indole-3-carbonitrile is used as a starting material for the preparation of indole derivatives, which can be further utilized in the development of agrochemicals for crop protection and pest control.
Used in Drug Discovery and Development:
7-amino-4-methyl-1H-indole-3-carbonitrile is used as a valuable compound in drug discovery and development due to its potential biological activities. Its unique structure and properties make it a promising candidate for the design and synthesis of novel therapeutic agents.
Used in Anticancer Applications:
7-amino-4-methyl-1H-indole-3-carbonitrile has been studied for its anticancer activities. It may be used as a potential therapeutic agent or a component in the development of anticancer drugs, targeting various types of cancer cells.
Used in Antifungal and Antibacterial Applications:
7-amino-4-methyl-1H-indole-3-carbonitrile has demonstrated antifungal and antibacterial activities, making it a potential candidate for the development of anti-infective agents. It can be used in the synthesis of new antimicrobial compounds to combat resistant strains and improve treatment outcomes.

Upstream product

• 289483-82-5 3-Cyano-4-methyl-7-nitro-1H-indole 
• 289483-86-9 7-(N-tert-Butoxycarbonyl)amino-3-cyano-4-methyl-1H-indole 
• 165669-07-8 7-Bromo-4-methyl-1H-indole 
• 289483-83-6 4-Methyl-1H-indole-7-carboxylic acid 
• 289483-84-7 tert-butyl N-(4-methyl-1H-indol-7-yl)carbamate 
• 289483-85-8 tert-butyl N-(3-formyl-4-methyl-1H-indol-7-yl)carbamate 
• 5326-34-1 4-Bromo-3-nitrotoluene 
• 289483-81-4 3-Formyl-4-methyl-7-nitro-1H-indole 
• 289483-80-3 4-methyl-7-nitro-1H-indole 

Downstream Products

• 289483-69-8 N-(3-cyano-4-methyl-1H-indole-7-yl)-3-cyanobenzenesulfonamide 

Relevant academic research and scientific papers

SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION

DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Process for preparing sulfonamide-containing indole compounds

A process for preparing a compound (5a) represented by the following formula: wherein R1 and R2 each independently represent hydrogen, C1-4 alkyl, etc. and A represents cyanophenyl, etc., characterized by reacting a compou

CRYSTAL OF SULFONAMIDE-CONTAINING INDOLE COMPOUND AND PROCESS FOR PRODUCING THE SAME

A crystalline form of N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide having a diffraction peak at a diffraction angle (2θ ± 0.2°) of 19.1° in a powder X-ray diffraction.

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

INTEGRIN EXPRESSION INHIBITORS

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, -CH=CH- or - (CR4bR5b)mb- (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or -CO-NH-; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Sulfonamide-containing indole compounds

The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1-C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1-C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R1 is cyano group or a halogen atom, at least one of R2 and R3 should not be a hydrogen atom.